Molecular testing has been increasingly utilized to assist with indeterminates as approximately seventy percent of differentiated thyroid cancers have detectable abnormalities involving BRAF, RAS, RET/PTC, or PAX8/PPAR gamma. Here, RET is linked to thyroid cancer.